Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Core Insights - Aligos Therapeutics, Inc. announced the adoption of the nonproprietary name "pevifoscorvir sodium" for its investigational drug ALG-000184, aimed at treating chronic hepatitis B virus (HBV) infection [1][3] Company Overview - Aligos Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases, with a mission to improve patient outcomes [5] - The company utilizes a science-driven approach and has a pipeline targeting high unmet medical needs, including chronic HBV infection and metabolic dysfunction-associated steatohepatitis (MASH) [5] Drug Development - Pevifoscorvir sodium is a potential first-in-class oral small molecule capsid assembly modulator (CAM-E) for chronic HBV infection, derived from intellectual property licensed from Emory University [4] - Phase 1 studies indicated that pevifoscorvir sodium was well-tolerated, showing no safety signals and demonstrating linear pharmacokinetics and excellent antiviral activity [4] - The drug has shown sustained reductions in HBV DNA, RNA, HBsAg, HBeAg, and HBcrAg in longer-term Phase 1 studies [4] - The Phase 2 B-SUPREME study was initiated in August 2025, with interim data expected in 2026 and topline data anticipated in 2027 [4] Regulatory and Naming Significance - The adoption of the generic name ensures consistent identification and supports international recognition and transparency across markets [3] - The regulatory path for pevifoscorvir sodium has been acknowledged by the FDA, EMA, and NMPA (China) for subsequent studies utilizing the chronic suppressive pathway [4]